Oxford BioDynamics (LON:OBD) Reaches New 1-Year Low – Should You Sell?

Oxford BioDynamics Plc (LON:OBDGet Free Report) reached a new 52-week low during trading on Tuesday . The stock traded as low as GBX 0.16 and last traded at GBX 0.17, with a volume of 14546039 shares changing hands. The stock had previously closed at GBX 0.17.

Oxford BioDynamics Price Performance

The company’s fifty day moving average is GBX 0.20 and its 200 day moving average is GBX 0.24. The company has a quick ratio of 2.80, a current ratio of 0.88 and a debt-to-equity ratio of 457.97. The stock has a market cap of £7.29 million, a PE ratio of -0.21 and a beta of 0.42.

Oxford BioDynamics Company Profile

(Get Free Report)

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.

Featured Stories

Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.